Abstract
The incidence of mosaicism at blastocyst stage using next generation sequencing (NGS) method is highly variable between clinics, ranging from as low as 2% to as high as 40%. A consistent high incidence of mosaic embryos in some clinics may be indicative of clinical treatment, embryology, analysis approach or in some cases be patient-related factors (Fragouli et al., 2019). However, little is known about the influence of biopsy protocol on the rate of mosaicism in preimplantation genetic testing for aneuploidy (PGT-A) cycles.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
